Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nevirapine

FDA-approved product (tablet, oral), marketed as Nevirapine, Viramune, Viramune Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nevirapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nevirapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nevirapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study

    NCT03916328 · start 2019-12-03

    Registered record
    Registry ID
    NCT03916328
    Conditions
    Bone Loss
    Interventions
    B/F/TAF; TDF/3TC/EFV or DTG or NVP; DMPA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-12-03
    Completion
    2024-03-31
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Loss
    InterventionB/F/TAF; TDF/3TC/EFV or DTG or NVP; DMPA
    PhasePhase 4
    Registry statusUnknown

  • Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals

    NCT03723525 · start 2018-01-22

    Registered record
    Registry ID
    NCT03723525
    Conditions
    HIV
    Interventions
    Package of HIV care; Standard HIV care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-22
    Completion
    2019-12-24
    Enrolment
    1,073

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionPackage of HIV care; Standard HIV care
    PhasePhase 4
    Registry statusCompleted

  • HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure

    NCT03642704 · start 2017-02-22

    Registered record
    Registry ID
    NCT03642704
    Conditions
    Mother to Child HIV Transmission
    Interventions
    Reinforced preventive ARV therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-02-22
    Completion
    2019-09-17
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMother to Child HIV Transmission
    InterventionReinforced preventive ARV therapy
    PhasePhase 4
    Registry statusCompleted

  • Nevirapine + 3TC Based Maintenance Therapy for HIV Infection

    NCT03223402 · start 2016-12-23

    Registered record
    Registry ID
    NCT03223402
    Conditions
    HIV Infections
    Interventions
    Nevirapine plus lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-12-23
    Completion
    2018-05-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine plus lamivudine
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of the Effectiveness of a Quality Improvement Intervention

    NCT04278612 · start 2016-01-18

    Registered record
    Registry ID
    NCT04278612
    Conditions
    Maternal and Child Health
    Interventions
    Quality improvement intervention to strengthen health service provision
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-01-18
    Completion
    2019-01-16
    Enrolment
    1,438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMaternal and Child Health
    InterventionQuality improvement intervention to strengthen health service provision
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

    NCT02431975 · start 2015-08

    Registered record
    Registry ID
    NCT02431975
    Conditions
    HIV
    Interventions
    Nevirapine; Zidovudine; Lamivudine; LPV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08
    Completion
    2020-04-30
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionNevirapine; Zidovudine; Lamivudine; LPV/r
    PhasePhase 4
    Registry statusCompleted

  • Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

    NCT02140255 · start 2015-01-23

    Registered record
    Registry ID
    NCT02140255
    Conditions
    HIV Infection
    Interventions
    Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL); VRC01; Dolutegravir (DTG); VRC07-523LS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2015-01-23
    Completion
    2031-12-31
    Enrolment
    1,120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL) +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

    NCT02104700 · start 2014-04

    Registered record
    Registry ID
    NCT02104700
    Conditions
    HIV
    Interventions
    Rilpivirine/Emtricitabine/Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRilpivirine/Emtricitabine/Tenofovir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

    NCT01789879 · start 2014-03-04

    Registered record
    Registry ID
    NCT01789879
    Conditions
    HIV; Contraception
    Interventions
    Levonorgestrel; Nevirapine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2015-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Contraception
    InterventionLevonorgestrel; Nevirapine; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

    NCT01435018 · start 2013-10-01

    Registered record
    Registry ID
    NCT01435018
    Conditions
    HIV-1 Infection
    Interventions
    Etoposide (ET); Bleomycin and Vincristine (BV); Paclitaxel (PTX); Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2019-08-29
    Enrolment
    334

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionEtoposide (ET); Bleomycin and Vincristine (BV); Paclitaxel (PTX); Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
    PhasePhase 3
    Registry statusCompleted

  • Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

    NCT01410058 · start 2013-01

    Registered record
    Registry ID
    NCT01410058
    Conditions
    HIV
    Interventions
    Moringa oleifera; Efavirenz 600mg; Nevirapine 200Mg Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-09
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMoringa oleifera; Efavirenz 600mg; Nevirapine 200Mg Oral Tablet
    PhaseNot recorded
    Registry statusCompleted

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted